All in all, current knowledge reflects the future potential of deciphering the association between blood-based EGFR detection and MRD dynamic monitoring, which could further support the early detection of NSCLC recurrence and the targeted individualized prognosis prediction. This evidence concerns the gene EGFR and non-small cell lung carcinoma.